• High-Throughput BBB Permeability Prediction via LLC-PK1-MDR1

  2026-05-25

  This study introduces a high-throughput in vitro blood-brain barrier (BBB) model that integrates LLC-PK1-MOCK/MDR1 cells and lysosomal trapping corrections to enhance the prediction of CNS drug permeability. The approach demonstrates strong correlation with in vivo brain distribution, providing a robust tool for early-stage CNS drug screening and prioritization.

• Applied Workflows with Substance P: Tachykinin Neuropeptide

  2026-05-25

  Unlock advanced pain and inflammation research with Substance P, a tachykinin neuropeptide uniquely suited for mechanistic and translational studies. This guide details optimized protocols, troubleshooting tips, and the latest spectral analytics, equipping labs to achieve reproducibility and new biological insight.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu

  2026-05-24

  The reference study introduces a robust protocol to generate human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) for pharmacokinetic research, offering a more physiologically relevant in vitro model for investigating oral drug metabolism. This advancement addresses limitations of traditional models and enables precise evaluation of CYP2C19 substrate metabolism in human-relevant systems.

• Modelling Pulmonary Drug Permeability: Advances in Biomimeti

  2026-05-23

  This study introduces a robust, mass spectrometry-compatible approach for modeling lung permeability of pharmaceuticals using biomimetic chromatography. By comparing immobilised artificial membrane (IAM) liquid chromatography and open tubular capillary electrochromatography (OT-CEC), the research establishes new standards for high-throughput permeability screening, with significant implications for respiratory drug development and inhaled corticosteroid studies.

• High-Throughput BBB Permeability Prediction with Surrogate M

  2026-05-22

  The reference study introduces a robust in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells combined with lysosomal trapping correction, enabling high-throughput and predictive screening of CNS drug candidates. This platform improves the reliability of BBB permeability assessment and streamlines early-stage CNS drug development workflows.

• Cimetidine as a Histamine-2 Receptor Antagonist in Barrier M

  2026-05-22

  Cimetidine’s distinct partial agonist profile enables advanced interrogation of H2 receptor signaling in both gastrointestinal cancer and blood-brain barrier (BBB) models. With high solubility and validated purity, it empowers reproducible, high-throughput workflows that stand apart from conventional H2 antagonists.

• ERAD-Hijacking Chimeras Enable Precise TM Protein Degradatio

  2026-05-21

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that hijacks ER-associated degradation (ERAD) for selective elimination of transmembrane proteins. This innovation addresses a critical gap in targeted protein degradation strategies, offering new avenues for research and potential therapeutic applications.

• ERAD-Engaging Chimeras Enable Selective TM Protein Degradati

  2026-05-21

  Song et al. (2026) introduce ERAD-engaging chimeras (ERADECs), a novel class of small molecules that hijack the ER-associated degradation pathway to induce selective degradation of transmembrane proteins. This approach overcomes previous technical barriers in targeted protein degradation and opens new avenues for disease-related membrane protein modulation.

• Palonosetron Hydrochloride: Precision 5-HT3 Antagonist for R

  2026-05-20

  Palonosetron hydrochloride offers unmatched specificity and duration as a 5-HT3 receptor antagonist, optimizing in vitro and in vivo antiemetic workflows. Its dual-site binding and ultra-low IC50s empower both cancer research and transporter studies with superior reproducibility.

• Distinguishing Proliferative Arrest and Cell Death in Cancer

  2026-05-20

  Schwartz's dissertation introduces a rigorous distinction between proliferative arrest and cell death when evaluating anti-cancer drug responses in vitro. By dissecting these mechanisms, the study enables more precise interpretation of anti-proliferative agent efficacy, informing assay design and data analysis strategies for cancer research.

• Fluorescent RNA Labeling: Advancing Probe Design for Transla

  2026-05-19

  This thought-leadership article explores how the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit empowers translational researchers to address key mechanistic and workflow challenges in RNA probe synthesis, with insights that bridge advanced fluorescence detection, macrophage efferocytosis biology, and emerging therapeutic strategies.

• Pentoxifylline in Translational Inflammation Models: Mechani

  2026-05-19

  Explore how Pentoxifylline, a potent phosphodiesterase inhibitor, advances translational inflammation research. This article uniquely examines mechanistic subtleties and practical assay design, empowering scientists to optimize protocols and interpret outcomes with confidence.

• FXR-KLF11 Axis: CDCA Mitigates CI-AKI via JAK2/STAT3 Suppres

  2026-05-18

  This study demonstrates that Chenodeoxycholic Acid (CDCA) activates FXR to transcriptionally upregulate KLF11, leading to suppression of the JAK2/STAT3 pathway and protection against contrast-induced acute kidney injury (CI-AKI). These findings offer a mechanistic rationale for targeting the FXR-KLF11 axis in translational research on renal injury and nuclear receptor signaling.

• Dissecting Cell Fate: In Vitro Evaluation of Cancer Drug Res

  2026-05-18

  Schwartz's dissertation advances in vitro drug evaluation by distinguishing between proliferative arrest and cell death, revealing that anti-cancer agents often modulate both processes with distinct kinetics. This nuanced perspective enables more accurate mechanistic profiling and benchmarking of anti-proliferative agents in preclinical cancer research.

• Palonosetron Hydrochloride: Molecular Precision and Clinical

  2026-05-17

  Discover the advanced mechanisms of Palonosetron hydrochloride, a highly selective 5-HT3 receptor antagonist, and its profound implications for chemotherapy-induced nausea and vomiting prevention. This article uniquely bridges molecular pharmacology with translational workflows and clinical decision-making.

401 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page